Pharma-Bio Serv, Inc. PBSV revenue by segment, product and geography
In its fiscal year ending 2025-10-31, Pharma-Bio Serv, Inc. reported revenue across 4 geographies; the largest, Puerto Rico Consulting, was $4.64M, 51.5% of the filed sum (-18.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Puerto Rico Consulting$4.64M51.5%-18.5% yoy
- United States Consulting$2.62M29.1%-17.1% yoy
- Europe Consulting$1.73M19.2%+202.4% yoy
- Other Segment$16.7K0.2%-80.6% yoy
Members sum to the consolidated $9M for this period.
- Puerto Rico Consulting$1.45M53.7%+24.0% yoy
- Europe Consulting$626K23.1%+17.4% yoy
- United States Consulting$620K22.9%-13.2% yoy
- Other Segment$6.56K0.2%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.